Impact of adherence on duration of virological suppression among patients receiving combination antiretroviral therapy

HIV Medicine

Volumn 3, Issue 2, 2002, Pages 118-124

  Raboud, J M ^a   Harris, M ^b   Rae, S ^c   Montaner, J S G ^b,d  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c Breast Cancer International Research Group   (Canada)

^d Canadian HIV Trials Network   (Canada)

Author keywords

Adherence; Antiretroviral therapy; Combination therapy; Viral load

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; VIRUS RNA; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROBABILITY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SELF REPORT; SENSITIVITY ANALYSIS; TREATMENT FAILURE; VIRUS LOAD;

ANTI-HIV AGENTS; DRUG THERAPY, COMBINATION; HUMANS; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIALS; VIRAL LOAD;

EID: 0036262198     PISSN: 14642662     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-1293.2002.00109.x     Document Type: Article

References (27)

1. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy
2. Long-term patient adherence to antiretroviral therapy
3. Factors affecting adherence to antiretroviral therapy
4. Medication adherence among HIV-infected patients. Understanding the complex behaviour of patients taking this complex therapy
5. Management of the adverse effects of antiretroviral therapy and medication adherence
6. Adherence: A necessity for successful HIV combination therapy
7. Clinical outcome and predictive factors of failure of highly active antiretroviral therapy in antiretroviral-experienced patients in advanced stages of HIV-1 infection
8. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection
9. Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens
10. Adherence of human immunodeficiency virus-infected patients to antiretroviral therapy
11. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response
12. Adherence to triple therapy and viral load response
13. The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir
14. Suppression of plasma viral load below 20 copies/mL is required to achieve a long-term response to therapy
15. A randomized, double blinded trial comparing combinations of nevirapine, didanosine and zidovudine for HIV infected patients. The INCAS trial
16. AVANTI 2: Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patients
17. AVANTI 3: A randomized, double-blind trial to compare the efficacy and safety of lamivudine plus zidovudine versus lamivudine plus zidovudine plus nelfinavir in HIV-1-infected antiretroviral-naive patients
18. Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: Application to acute retroviral infection
19. A rapid and simple method for extracting human immunodeficiency virus type 1 RNA from plasma: Enhanced sensitivity
20. Ultrasensitive reverse transcription-PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma
21. Monitoring adherence to HIV therapy
22. Determinants of heterogeneous adherence to HIV-antiretroviral therapies in the Multicenter AIDS Cohort Study
23. Antiviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel
24. Adherence to protease inhibitors
25. Definition and measurement of adherence to antiretroviral drugs in HIV-1 infected patients
26. Patient-reported nonadherence to HAART is related to protease inhibitor levels
27. Do dual nucleoside regimens have a role in the era of viral load driven antiretroviral therapy?